hUCB
BiologicalhUCB
NCT Number: NCT06377982
A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy
Trial opening soon.
Get Notified1 year–18 year
All sexes
Interventional
Phase 1
This is a phase I study to evaluate the safety and efficacy in hUCB treatment on the patients with cerebral palsy (CP).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
hUCB
Time frame: From screening to 56 weeks
Frequency and incidence of treatment-emergent adverse events (TEAEs).
Contact information is provided by the study sponsor or research team.
StemCyte Taiwan Co., Ltd.
Industry
A Phase I, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Safety and Efficacy of Allogeneic Human Umbilical Cord Blood Infusion in Children with Cerebral Palsy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07732205
Brain Damage, Chronic, Brain Diseases
Budapest, Pest County, Hungary
View Trial DetailsNCT07469514
Brain Damage, Chronic, Brain Diseases
Oakland, California, United States
View Trial DetailsNCT07702786
Brain Damage, Chronic, Brain Diseases
View Trial DetailsNCT07683455
Behavior, Brain Damage, Chronic
View Trial Details